The last few decades have witnessed a steady increase in the proportion of myocardial perfusion imaging (MPI) tests that utilize pharmacologic stress instead of exercise.
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Aminophylline, a nonselective adenosine receptor antagonist, has been available on the market for decades and used to reverse the adverse effects of dipyridamole and adenosine and more recently been shown to be safe and effective for use with regadenoson. 8, 9 In this issue of the Journal, Fughhi et al. 10 address the concern that use of aminophylline to ameliorate the adverse effects of regadenoson may reverse its effects on coronary vasodilation and subsequent myocardial hyperemia reducing the sensitivity of MPI for detecting perfusion abnormalities. The data for the current study were pooled from two double-blinded, placebo-controlled randomized clinical trials, the ASSUAGE and ASSUAGE-CKD trials, 9, 11 which demonstrated the effectiveness of aminophylline in attenuating the adverse effects associated with regadenoson in patients undergoing MPI. In both trials, patients were randomized to receive 75 mg of intravenous aminophylline or placebo administered at 90 seconds after radioisotope injection (*2 minutes following regadenoson). The primary end point of the current report was the degree of reversibility of the perfusion defect on imaging as measured by the semi-quantitative summed difference score (SDS). The secondary end point was the presence of myocardial ischemia as defined by SDS C2. The authors also examined the effect of aminophylline use on the prognostic value of myocardial ischemia detection by MPI for cardiac events including cardiac death, myocardial infarction (MI), and coronary revascularization over a follow-up period of 29 ± 14 months.
The myocardial ischemic burden (primary outcome) and the presence of myocardial ischemia (secondary outcome) on MPI were similar between the two groups. However, there was a trend towards a higher proportion of abnormal perfusion (summed stress score, SSS C4, 34% vs 27%, P = .08) in the placebo group that the authors attributed to the significantly higher rate of prior MI (20% vs 13%, P = .03) in this group. To account for this imbalance, the authors performed a sensitivity analysis in patients without clinical or MPI evidence (summed rest score, SRS C4) of prior MI, and demonstrated similar prevalence of myocardial ischemia and abnormal perfusion between the two groups. There was no difference in the event-free survival between the study groups after adjusting for SDS, SRS, prior MI, and left ventricular ejection fraction, and no interaction between aminophylline use and SDS or myocardial ischemia (SDS C2) as a determinant of cardiac events in the overall cohort and after excluding patients with prior MI. Reassuringly, there was no difference in events between the two groups in the cohort of patients with normal perfusion on imaging. The authors concluded that aminophylline administration *2 minutes after regadenoson injection ameliorated regadenoson-induced adverse effects without a detectable effect on the diagnostic performance of MPI.
Following IV bolus administration of regadenoson, the maximal venous plasma concentration of the drug is usually reached after 1-3 minutes and myocardial blood flow (MBF) velocity increases by [2.5 folds for at least 2 minutes allowing for adequate radionuclide uptake which is a prerequisite for successful MPI 12 (Figure 1A) . In the study by Lieu et al., 12 the peak MBF velocity (3.1 ± 0.5 fold) associated with 400 lg IV bolus of regadenoson was reached within 0.5-2.3 minutes with a mean of 33 seconds (range of 20-40 seconds) to reach C85% of maximal flow. In addition, the increase in peak flow velocity by[2.5-fold was maintained for a mean of 2.3 minutes. In the same study, administration of 100 mg IV aminophylline at 1 minute after regadenoson did not alter peak MBF increase but it did significantly abbreviate regadenoson-induced Figure 1 . (A) Time dependence of 400 and 500 lg of IV regadenoson bolus on average peak coronary flow velocity (APV) ratio; (B) Effects of 400 lg of IV regadenoson bolus on APV ratio and heart rate before and after administration of 100 mg of IV aminophylline (modified from Lieu et al. 12 and Zoghbi et al. 24 ).
coronary hyperemia ( Figure 1B ) raising concerns that early administration of an adenosine receptor antagonist after a regadenoson bolus may attenuate MPI abnormalities. 12 In a canine model of ischemia that evaluated myocardial uptake and clearance of 99 mTc-tetrofosmin relative to microsphere flow, Sinusas et al. 13 demonstrated that 99 mTc-tetrofosmin cleared rapidly from the blood and was retained by the myocardium whereby its uptake and clearance by ischemic and non-ischemic myocardium plateaus almost 100 seconds after its injection. Similarly, Takahashi et al. 14 showed in bloodperfused rat hearts that the net tissue extraction of 99 mTc-tetrofosmin plateaus within 100 seconds.
14 Thus, at least theoretically, antagonism of adenosine receptors at least 100 seconds after regadenoson administration should not interfere with myocardial uptake of the tracer. Based on these data, and allowing 10 seconds for the drug to reach the coronary capillary bed, The ASSUAGE trials, on which the study by Fughhi et al. 10 is based, administered aminophylline at 90 seconds after tracer administration.
It is important to interpret the results of the study by Fughhi et al. 10 with caution since the findings are based on post hoc analysis of studies that were not designed or powered to address this issue. As pointed out earlier, the higher prevalence of abnormal myocardial perfusion in the placebo group is another reason to pause when interpreting the findings although the authors have attributed this to the imbalance in the distribution of patients with prior MI between the 2 randomized groups. Ultimately, the optimal study to assess the effect of aminophylline on the diagnostic performance of regadenoson MPI would be a crossover clinical trial in which patients, in addition to the rest scan, undergo two stress scans and are randomized to receive aminophylline or placebo after regadenoson administration. The proper analysis of such a study has been discussed previously. 15 Caffeine, another adenosine receptor antagonist, also has the potential to oppose the effects of regadenoson. 16 A recent study investigated the use of IV and oral caffeine as a potential alternative to aminophylline for the reversal of regadenoson-induced adverse effects. 17 The significance of prior caffeine consumption on regadenosoninduced coronary hyperemia and the diagnostic sensitivity of MPI for detection of perfusion abnormalities have been recently debated in the Journal. [18] [19] [20] [21] [22] Our view is that moderate caffeine consumption (i.e., B2 cups of coffee more than 1 hour prior to presentation to the stress laboratory) does not alter coronary flow reserve to such an extent to significantly impact myocardial perfusion pattern on MPI. In line with this view, the recently released American Society of Nuclear Cardiology imaging guidelines for SPECT nuclear cardiology procedures: Stress protocols and tracers states that ingestion of caffeinated foods or beverages within the last 12 hours prior to regadenoson MPI (or other vasodilator stress agents) should be avoided but downgraded this from an absolute to a relative contraindication. 23 The study by Fughhi et al. 10 provides some reassurance that administration of aminophylline, when delayed by at least 2 minutes, does not substantially interfere with the effects of regadenoson on myocardial perfusion by MPI. Therefore, when significant complications are encountered as summarized in the recent guidelines, 23 reversal of regadenoson should be considered without concern for altering findings on imaging. Whether reversal of regadenoson using IV aminophylline or caffeine should be undertaken on a routine basis irrespective of symptom development continues to be a matter of debate.
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